Robotic Surgery Archives - Page 7 of 8 - Medical Design Sourcing

FDA clears Zimmer Biomet partial knee system for its Rosa system

Zimmer Biomet today said it received FDA 510(k) clearance for its Rosa Partial Knee system for robotically-assisted partial knee replacement surgeries.

Rosa Partial Knee is the latest addition to Zimmer Biomet’s Rosa Robotics platform, which includes the Rosa Knee system for total knee replacement surgery and Rosa One for neurosurgical and spine procedures. The Rosa Partial Knee is also a part of the company’s ZBEdge.

The partial knee system is designed for compatibility with Zimmer Biomet’s Persona Partial Knee. It has 2D and 3D X-Atlas imaging technology with real-time, intraoperative data collection on soft tissue and bone anatomy to improve bone cut accuracy and range of motion gap analysis.

“The FDA clearance of the Rosa Partial Knee system just two years after the introduction of the Rosa Total Knee system builds on the success of our Rosa robotics portfolio, which is designed to help enhance surgical accuracy, precision and…

Vicarious Surgical to go public in $1.1B SPAC deal

[Image courtesy of Vicarious Surgical]Vicarious Surgical will go public through a $1.1 billion special purpose acquisition company (SPAC) deal, the robotic surgery pioneer announced today.

Vicarious, which has sought to bring robotics and virtual reality to minimally invasive surgery, will trade on the New York Stock Exchange under the symbol RBOT after the merger with D8 Holdings.

Hong Kong–based D8 Holdings’ acquisition of Vicarious Surgical will add more than $425 million in cash to Vicarious’s balance sheet upon the deal’s close, including a $115 million private investment in public equity (PIPE) priced at $10 per share. Pipe investors include strategic investor BD, new institutional investors and existing investors including Bill Gates, Vinod Khosla’s Khosla Ventures, Eric Schmidt’s Innovation Endeavors, and Philip Liang’s E15 VC.

The SPAC deal comes nearly a year and a half after FDA provided breakthrough device des…

ForSight Robotics raises $10M for ophthalmic robotic surgery platform

Forsight Robotics, a developer of a robotic surgical platform for ophthalmic procedures, has reportedly raised $10 million.

According to a report from TechCrunch, the seed round of financing was led by Eclipse Ventures and Mithril Capital and is earmarked to be used for expanding the company’s headcount and global reach as it sets its sights on launching its robotic surgery platform in multiple markets around the globe.

The Isreal-based company’s robotic surgical platform is designed to utilize microsurgical technology, advanced visualization and machine learning to produce automated ophthalmic procedures that offer precision and cost-effectiveness, according to the company’s website.

According to CTech, the company, which employs 15 people at present, was founded by Moshe Shoham, the founder of Mazor Robotics, which was bought by Medtronic for $1.7 billion.

Additionally, Intuitive Surgical and Auris Health (now part of Johnson &…

Stereotaxis up on Street-beating Q4 results

Shares of Stereotaxis (NYSE:STXS) shot up in morning trading today after the robotic surgery company reported Street-beating Q4 results and predicted double-digit revenue growth this year.

The St. Louis–based company, creator of robotic technologies for the treatment of cardiac arrhythmias, reported a loss of –$1.18 million, or –2¢ share, on sales of $6.82 million for the three months ended Dec. 31, 2020, versus a loss of $1.08 million, or –2¢ per share, on sales of $6.89 million in Q4 2019.

Earnings were a penny ahead of The Street, where analysts predicted a loss of –3¢ per share on sales of $6.03 million.

CEO David Fischel said 2020 was a year of significant progress, despite the challenges of the COVID-19 pandemic.

“The highlight of the year was receipt of FDA clearance for the Genesis RMN System and successful installations of the first systems in the United States and Europe. We begin 2021 with purchase orders for five robotic systems reflec…

Titan Medical brings in another $23 million

Titan Medical (TSX:TMD;OTC:TITFX) today announced the closing of a $23 million bought deal.

The Toronto-based surgical robotics company conducted the sale by way of a short form prospectus in each of the provinces of British Columbia, Alberta and Ontario — as well as a private placement in the U.S. Last month, Titan Medical raised an additional $21.5 million in two additional bought-deal offerings announced on Jan. 5 and Jan. 26.

“It’s been a very active season for Titan Medical Inc. We are in better shape than we have ever been, and we’re looking forward to an exciting 2021,” CFO Monique L. Delorme told MassDevice.

Titan president & CEO David McNally noted in an earnings news release out on Feb. 22 that the company in 2020 executed a license agreement and a separate development and license agreement with Medtronic. The result was the company’s first revenue of $20 million, by way of license payments.

“We believe Titan …

BREAKING: TransEnterix announces name change, new category of surgery

TransEnterix (NYSE:TRXC) announced today that it will change its name to Asensus Surgical and introduce a new category of surgery to its offerings.

Research Triangle Park, N.C.-based Asensus Surgical said in a news release that its name change represents its broader vision of shaping the future of surgery by integrating computer vision and machine learning with surgical robotics. Sensus is Latin for “cognition,” highlighting the connection between surgeons’ knowledge and the augmented intelligence technology, the company said.

Including “A” ahead of “sensus” is a hat-tip to augmented intelligence, while “Asensus” also represents “ascending” and elevating” as a tribute to the company’s efforts to elevate robotic surgery.

As a result of the name change, which is effective today, Asensus stock will begin trading under the ASXC ticker on the New York Stock Exchange at the open of t…

Could artificial intelligence boost surgical robotics to new heights?

Goldberg and his team trained a da Vinci surgical robot to automatically perform peg transfer slightly faster and more accurately than an experienced surgical resident. [Image courtesy of the Autolab at UC Berkeley]Ken Goldberg thinks artificial intelligence will enable surgical robots to achieve their best function — not replacing surgeons but augmenting their work by reducing the monotony of specific subtasks like suturing.

The William S. Floyd Jr. Distinguished Chair in Engineering at UC Berkeley, Goldberg and his research team have continued to advance the field.

The group — which includes postdoctoral researchers Minho Hwang and Jeffrey Ichnowski and PhD student Brijen Thananjeyan — has demonstrated how a deep neural network plus 3D-printed depth-sensing markers can train a da Vinci surgical robot to automatically perform peg transfer slightly faster and more accurately than an experienced surgical resident.

They also published a paper in Science Robot…

TransEnterix brings in $79.6M from stock offering

TransEnterix (NYSE:TRXC) recently announced that it has closed on a public offering of more than 26.5 million shares of its common stock, with roughly $79.6 million in aggregate gross proceeds for the surgical robotics company.

The offering, in combination with recent financing activity, extends TransEnterix’s cash runway into 2024. The money will go toward general corporate purposes, including working capital, product development and capital expenditures.

H.C. Wainwright & Co. was the offering’s sole book-running manager.

News of the fundraising comes weeks after TransEnterix received CE Mark approval for its Intelligent Surgical Unit, which adds AI-based capabilities to the company’s Senhance robotic surgery system.

Titan Medical closes on $11.5M offering

Titan Medical (TSX:TMD; NSDQ:TMDI) announced today that it has closed on a previously announced offering, raising $11.5 million in aggregate gross proceeds.

The Toronto-based surgical robotics company conducted the sale by way of a short form prospectus in each of the provinces of British Columbia, Alberta and Ontario — as well as a private placement in the U.S.

The offering included nearly 6.5 million company units sold on a “bought deal” basis for gross proceeds of roughly $10 million, with underwriter Bloom Burton Securities exercising its over-allotment option in full for an additional 967,741 units and gross proceeds of $1.5 million.

The money will go toward the development of Titan Medical’s robotic surgical technologies and for general working capital.

DePuy Synthes lands FDA clearance for Velys robotic knee system

Image from Depuy Synthes/Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) unit DePuy Synthes announced that it received FDA 510(k) clearance for the Velys system.

Velys is a robotic-assisted system designed for use with the Attune total knee system and its cleared indications for use and it will become part of the broader Velys digital surgery platform of connected technologies, according to a news release.

DePuy Synthes touts the Velys robotic-assisted platform as a first-of-its kind, table-mounted solution with an efficient design capable of integrating into any operating room. The company said it adapts to a surgeon’s workflow, offers control they are used to and heps execute accurate bony cuts.

Additionally, the Velys system offers gap balance data for visualization and joint stability predictions, along with accurate, consistent plan execution supporting the Attune total knee system.

Johnson & Johnson and DePuy Synthes acquire…

Monteris Medical raises $9M

Monteris Medical (Plymouth, Minn.) has raised another $9 million, about four months after it crossed the 3,000 mark of people treated with its NeuroBlate robot-assisted brain surgery device.

The money came from a single investor, according to the Form D that Monteris filed today with the U.S. Securities and Exchange Commission. The company has been seeking a total $30 million in the present offering.

Funds are going toward further commercial expansion, CFO Jim Erickson told MassDevice via email.

Nearly all of the people treated so far with NeuroBlate had epilepsy, gliomas, brain metastases and radiation necrosis.

“Patients appreciate the minimally-invasive nature of NeuroBlate,” Dr. Stephan Schuele, chief of epilepsy and clinical neurophysiology at Northwestern Feinberg School of Medicine in Chicago, said in a May news release from Monteris announcing the 3,000th patient.

“They usually return home with a minimal hospital stay. It’s becom…

7 technologies to make a ‘new Medtronic’ even more powerful

[Original image from Unsplash]

It’s been four months since Geoff Martha took over the corner office at Medtronic (NYSE:MDT), and it’s becoming clear that he has ambitious plans for the world’s largest medical device company.

During the company’s Q1 earnings call on Aug. 25, Martha said management in coming weeks plans to outline plans for a “new Medtronic” that is more nimble and competitive. He touted the pipeline of products the company has built, saying that it was time to play offense and expand market share now that the pipeline is kicking in.

“We’re determined to make this pipeline count, not just for patients, our customers but for shareholders,” Martha said. He later added: “Over time, longer-term, we want to put the tech in medtech. And we want to shift, we want to pool in some of these digital technologies to change our offerings.”

Raj Denhoy and other Jefferies analysts in a research no…